Cancer Clinical Trials 2022

Browse 245 Cancer Medical Studies Across 544 Cities
28 Phase 3 Trial · 4203 Cancer Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Cancer Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Image of ArriVent Investigative Site in Fairfax, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Arm 1: Participants Receiving Dostarlimab + Carboplatin-paclitaxel Followed By Dostarlimabfor Cancer

This trial is testing a new immunotherapy drug combo against placebo to see if it's more effective in treating endometrial cancer.

Phase 3

Waitlist Available

FDA Approved Drug

GSK Investigational Site (+57 Sites)GSK Clinical TrialsTesaro, Inc.

Image of University of Alabama Birmingham in Birmingham, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

CC-95251for Cancer

This trial is testing a new drug, CC-95251, to see if it is safe and effective against solid and blood cancers.

Phase 1

Recruiting

FDA Approved Drug

University of Alabama Birmingham (+20 Sites)Amar Patel, MDCelgene

Image of GSK Investigational Site in La Jolla, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Lete-celfor Cancer

This trial will see if a new treatment is safe and tolerable for people with non-small cell lung cancer, with or without another existing treatment.

Phase 1 & 2

Waitlist Available

FDA Approved Drug

GSK Investigational Site (+18 Sites)GSK Clinical TrialsMerck Sharp & Dohme LLC

Image of University of Calgary/ Tom Baker Cancer Centre in Calgary, Canada.

Phase-Based Progress Estimates

Effectiveness

Safety

Exercisefor Cancer

This trial will evaluate whether the Alberta Cancer Exercise Program, which helps cancer patients get active, improves their quality of life and prevents secondary cancers.

Recruiting

Has No Placebo

University of Calgary/ Tom Baker Cancer Centre (+1 Sites)Nicole Culos-Reed, PhD

Image of Call for Information (Investigational Site 0002) in Grand Rapids, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

MK-8353for Cancer

This trial is testing the safety and effectiveness of a new drug, MK-8353, when used with another drug, pembrolizumab, to treat advanced malignancies (cancer). The study has two parts. In the first part, the recommended dose of MK-8353 will be determined. In the second part, the safety and effectiveness of the recommended dose will be checked in people with a certain type of advanced cancer (colorectal cancer that is microsatellite stable).

Phase 1

Waitlist Available

FDA Approved Drug

Call for Information (Investigational Site 0002) (+2 Sites)Medical DirectorMerck Sharp & Dohme Corp.

Image of Call for Information (Investigational Site 0013) in Gilbert, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Vibostolimabfor Cancer

This trial is testing a new drug, vibostolimab, for safety and efficacy as a treatment for metastatic solid tumors. The drug will be tested as monotherapy and in combination with pembrolizumab or pembrolizumab plus pemetrexed and carboplatin. The primary hypotheses are that vibostolimab is safe and tolerable when administered at the recommended Phase 2 dose, and that the fixed dose of pembrolizumab/vibostolimab coformulation is safe and tolerable.

Phase 1

Waitlist Available

FDA Approved Drug

Call for Information (Investigational Site 0013) (+8 Sites)Medical DirectorMerck Sharp & Dohme LLC

Image of Florida Cancer Specialists in Sarasota, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

BI 754091for Cancer

This trial is testing a drug to see if it is safe and effective for treating advanced solid malignancies. The trial will evaluate the drug's safety by monitoring for side effects, as well as its efficacy by measuring how well it shrinks tumors.

Phase 1

Waitlist Available

Has No Placebo

Florida Cancer Specialists (+10 Sites)Boehringer IngelheimBoehringer Ingelheim

Image of UPMC Cancer Centers in Pittsburgh, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

JNJ-63723283for Cancer

This trial is testing a new drug to see what dose is effective and how it works against different types of cancer.

Phase 1 & 2

Recruiting

Has No Placebo

UPMC Cancer CentersJanssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC

Image of GSK Investigational Site in Denver, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

GSK3326595for Cancer

This trial will assess the safety and preliminary clinical activity of GSK3326595 in people with advanced or recurrent solid tumors, or non-Hodgkin's lymphoma.

Phase 1

Waitlist Available

FDA Approved Drug

GSK Investigational Site (+10 Sites)GSK Clinical TrialsGlaxoSmithKline

Image of GSK Investigational Site in Duarte, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Feladilimab (GSK3359609)for Cancer

This trial is investigating the safety and effectiveness of the drug GSK3359609 as a treatment for various types of cancer. The study will be conducted in two parts, with each part having two phases. The primary objective is to determine the safety and tolerability of the drug.

Phase 1

Waitlist Available

FDA Approved Drug

GSK Investigational Site (+7 Sites)GSK Clinical TrialsMerck Sharp & Dohme LLC

Image of Call for Information (Investigational Site 0008) in Encinitas, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Favezelimab/Pembrolizumabfor Cancer

This trial is testing favezelimab as a possible treatment for people with metastatic solid tumors. The study will look at different doses of the drug and how well it works when used alone or in combination with other drugs.

Phase 1

Waitlist Available

FDA Approved Drug

Call for Information (Investigational Site 0008) (+5 Sites)Medical DirectorMerck Sharp & Dohme Corp.

Image of GSK Investigational Site in Birmingham, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Dostarlimabfor Cancer

This trial is testing a new drug for people with advanced solid tumors who have limited available treatment options. The study will evaluate the safety and effectiveness of the drug.

GSK Investigational Site (+49 Sites)GSK Clinical TrialsTesaro, Inc.

Phase-Based Progress Estimates

Effectiveness

Safety

ATLCAR.CD30 Cellsfor Lymphoproliferative Disorders

This trial is combining two different ways of fighting disease, antibodies and T cells, in order to create a more effective treatment against cancer.

Phase 1 & 2

Recruiting

Has No Placebo

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel HillAnne Beaven, MD

Phase-Based Progress Estimates

Effectiveness

Safety

ATLCAR.CD30 Cellsfor Cancer

This trial is testing a new way to fight cancer by combining T cells and antibodies. Researchers want to see if it's safe and if it has any side effects.

Phase 1

Waitlist Available

Has No Placebo

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill (+1 Sites)Thomas Shea, MD

Image of Norton Cancer Institute in Louisville, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Keytrudafor Cancer

This trial is testing the safety and effectiveness of VIP152 as a treatment for solid tumors and aggressive NHL.

Phase 1

Recruiting

Has No Placebo

Norton Cancer Institute (+11 Sites)Vincerx Study DirectorVincerx Pharma, Inc.

Image of National Institutes of Health Clinical Center, 9000 Rockville Pike in Bethesda, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Bortezomib Plus Clofarabinefor Myelodysplastic Syndromes

This trial is testing the safety and efficacy of the drug combination of bortezomib and clofarabine to treat cancer.

Phase 1

Recruiting

FDA Approved Drug

National Institutes of Health Clinical Center, 9000 Rockville Pike (+1 Sites)Naoko Takebe, M.D.

Image of Arrivent Investigative Site in Sacramento, United States.

Phase-Based Progress Estimates

Effectiveness

Safety

Furmonertinibfor Respiratory Tract Neoplasms

This trial is testing a new cancer drug to see if it is safe and effective. Patients with lung cancer caused by mutations in EGFR or HER2 may be eligible to participate.

Phase 1

Recruiting

Has No Placebo

Arrivent Investigative Site (+10 Sites)Morgan LamArriVent BioPharma, Inc.

25 Cancer Clinical Trials Near Me

Top Hospitals for Cancer Clinical Trials

Memorial Sloan Kettering Cancer Center

New York

25Active Trials

244All Time Trials for Cancer

1977First Cancer Trial

M D Anderson Cancer Center

Houston

20Active Trials

296All Time Trials for Cancer

1999First Cancer Trial

Top Cities for Cancer Clinical Trials

Los Angeles

97Active Trials

USC / Norris Comprehensive Cancer CenterTop Active Site

Boston

85Active Trials

Dana-Farber Cancer InstituteTop Active Site

Cancer Clinical Trials 2022

Browse 245 Cancer Medical Studies Across 544 Cities28 Phase 3 Trial · 4203 Cancer Clinics

Furmonertinib 160 Mgfor Cancer

Cemiplimabfor Cancer

FACTfor Parenting

Time-restricted Eatingfor Fatigue

5-Aminolevulinic Acid Hydrochloridefor Skull Base Neoplasms

PTeyefor Hypoparathyroidism

Intermittent Fastfor Cancer

Paclitaxelfor Cancer

Arm 1: Participants Receiving Dostarlimab + Carboplatin-paclitaxel Followed By Dostarlimabfor Cancer

CC-95251for Cancer

Lete-celfor Cancer

Exercisefor Cancer

MK-8353for Cancer

Vibostolimabfor Cancer

BI 754091for Cancer

JNJ-63723283for Cancer

GSK3326595for Cancer

Feladilimab (GSK3359609)for Cancer

Favezelimab/Pembrolizumabfor Cancer

Dostarlimabfor Cancer

ATLCAR.CD30 Cellsfor Lymphoproliferative Disorders

ATLCAR.CD30 Cellsfor Cancer

Keytrudafor Cancer

Bortezomib Plus Clofarabinefor Myelodysplastic Syndromes

Furmonertinibfor Respiratory Tract Neoplasms

Browse 245 Cancer Medical Studies Across 544 Cities
28 Phase 3 Trial · 4203 Cancer Clinics